Advertisement
Bethyl Laboratories
Bethyl Laboratories

Stem Cell Trials in Peril?

The only US firm with an ongoing embryonic stem cell therapy clinical trial is in financial and legal hot water.

By | January 27, 2014

WIKIMEDIA, LD711The Massachusetts-based firm Advanced Cell Technology has been leading the way in the somewhat fraught pursuit of developing therapies using human embryonic stem cells. After the 2010 failure of the stem cell company Geron, subsequent progress in clinical studies from Advanced Cell Technology offered a glimmer of hope. But a news report from Nature this week tossed cold water on any excitement—apparently, the company is in trouble with the U.S. Securities and Exchange Commission (SEC) and is running out of money.

“This is a very painful time for them,” Gregory Bonfiglio, a venture capitalist with Proteus Venture Partners in Portola Valley, California, told Nature.

Advanced Cell Technology is currently running three Phase I clinical trials for degenerative eye diseases. Although the company intends to start the next round of clinical trials later this year, Nature pointed out that the firm’s most recent quarterly report revealed that the its funds could dissipate this year.

Late in 2013, the company paid out $4 million to settle an SEC charge of selling stocks without registering them. Last week, Advanced Cell Technology’s CEO, Gary Rabin, stepped down. Rabin is the subject of an ongoing SEC investigation. And to make matters worse, the Wisconsin Alumni Research Foundation is suing Advanced Cell Technology for breach of contract.

Rabin’s interim replacement, Edward Myles, the company’s chief financial officer and executive vice president of corporate development, said in a press release that the clinical trials will proceed. “Our core programs, the ongoing Phase I clinical trials for dry-age related macular degeneration (AMD) and Stargardt’s macular degeneration (SMD), continue to progress according to plan and we expect to release interim, top line data from the trials in the very near future.”

Advertisement

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Comments

Avatar of: gizmo

gizmo

Posts: 1

January 27, 2014

Well, ACT is up 30% this morning.  I tend to pay attention to what the market does, rather than the pontifications of online writers who are not well-informed.  The company is about to announce the completion of their Phase I trial, in which there were no safety issues, and all patients experienced some level of therapeutic benefit.  This is almost unheard of in any FDA trial, especially one where safety & tolerability were the criteria, not efficacy.

Avatar of: Catchall

Catchall

Posts: 1

January 29, 2014

It reflects poorly on you to rely on another writers writing who says she meant to say while parsing her words. Call the company and see SEC notice initiated by them. They may have many years of financial protection to stand alone if the share price continues to increase.

Surprisingly to me coincidental with the recent articles which appear on the surface to be in the listing of problems business the marketplace is accumulating  shares. It may be any exposure encourages examination and the story of the company is bbbetter than either article purports it to be.

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
BioCision
BioCision
Advertisement